Novo Nordisk A/S Common Stock (NVO)

The financial markets are a dynamic arena where fortunes can shift rapidly, and the past week has seen two prominent companies, Palantir Technologies Inc. (NYSE: PLTR) and Viking Therapeutics (NASDAQ: VKTX), come under intense investor scrutiny. Despite a year of impressive gains for Palantir, concerns over its valuation have led

In a week marked by a surge of positive corporate news, three industry giants—Intel, Palo Alto Networks, and Novo Nordisk—have delivered significant boosts to investor confidence, signaling robust performance and strategic advancements across diverse sectors. These developments, ranging from substantial investments and strong earnings reports to groundbreaking drug

Novo Nordisk may pursue layoffs as its new CEO focuses on efficiency while facing intensifying obesity drug competition.

Novo’s website currently shows multiple job openings in the U.S. and mainland China, but merely eight open positions in Denmark.

There's more to the company's leading product than meets the eye.

Viking (VKTX) stock plunged 42% after its obesity pill trial. Experts are split: some call it a $129 Strong Buy, others say it's inferior.

San Diego, CA – Viking Therapeutics (NASDAQ: VKTX) experienced a dramatic stock decline today following the release of disappointing clinical trial results for its highly anticipated oral tablet designed to treat obesity and other metabolic disorders. The sharp downturn, which saw the company's shares plummet by over 30% in early trading,

Health Canada approved Ozempic for type 2 diabetes patients with chronic kidney disease after positive FLOW trial results.

UnitedHealth is down 38.85% YTD; Novo Nordisk is down 38.59%. Yet, their underlying strategies couldn't be more distinct.

For a cheap GLP-1 weight loss stock like Novo Nordisk, almost any news can help the stock pop.

Shares lost more than a third of their value after Viking unveiled mixed results for its oral VK2735.

The healthcare industry is one of the laggards of 2025.

GoodRx stock rose 5.08% after it partnered with Novo Nordisk to offer Ozempic and Wegovy at a flat $499 monthly price for self-paying patients.

A chip stock that recently partnered with NVIDIA. Now, a key company insider is buying over $160 million in shares, a bullish signal to investors.

Motley Fool Money checks in on some stock market news.

Investor risk sentiment paused at the start of the week, as markets awaited details expected to emerge later when President Donald Trump meets with Ukrainian President Volodymyr Zelenskyy and European leaders.

Dayforce shares skyrocketed 26% in Monday’s midday trade after reports suggested that private equity firm Thoma Bravo is in talks to acquire the human resources firm.

Novo Nordisk is showing signs that a comeback might be on the horizon after it hit the lows of its 52-week trading range.

The financial markets are abuzz with significant movements across various sectors, driven by a confluence of strategic investments, groundbreaking regulatory approvals, and the enduring influence of retail investor sentiment. From Warren Buffett's latest healthcare bet to the Trump administration's potential foray into semiconductor manufacturing, and a major pharmaceutical breakthrough, these

GoodRx and Novo Nordisk launch a $499 monthly self-pay option for Ozempic and Wegovy, expanding access at 70,000 pharmacies across the U.S.

Novo Nordisk stock looks so cheap, any good news at all can make it pop.

The new offer aims to assist Type 2 diabetes patients who are uninsured or choose to self-pay, and may potentially face prices at or above wholesale cost.

The FDA will allow patients with MASH to undergo Wegovy treatment, hampering the only other company with an approved MASH drug.